BIOGEN INC. (BIIB)
@BIIB.asset
$123.53
At close:
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
Figures
- Sector Healthcare
- Industry Biotechnology
- Index Nasdaq-100, S&P 500
- Market Cap $18.10 B
- Last Earnings Report May 1, 2025
- Price Reaction to Earnings Report -2.67%
- Enterprise Value $21.80 B
- P/E ratio 12.18
- Price/Sales ratio 1.84
- EV/Sales ratio 2.22
- Price/Book Value 1.06
- Revenue $9.82 B
- EBIT $0.00 B
- Net Income $1.48 B
- Gross Profit $7.42 B
- Free Cash Flow $2.53 B
- EBIT Margin ?%
- Gross Margin 75.58%
- FCF Margin 25.73%
- Return on Equity 8.71%
- Equity Ratio 60.57%
- Debt/Equity Ratio 0.65
- 6-month Performance -28.92%
- 12-month Performance -42.14%
- Trend reversal neutral
What the community is saying
| Nobody said anything, yet! Speak your mind and be the first to create a new topic. |